AstraZeneca’s Lynparza Plus Imfinzi Receives the CHMP’s Positive Opinion for Treating Endometrial Cancer
Shots:
- The CHMP’s positive opinion of Imfinzi + CT followed by Lynparza & Imfinzi (pMMR disease) or Imfinzi alone (dMMR disease) was supported by a prespecified exploratory subgroup analysis from P-III (DUO-E) study. Review of further submissions for the same is underway in Japan & other regions
- The P-III (DUO-E) study assessed 1L Imfinzi + CT (carboplatin & paclitaxel) followed by either Imfinzi alone or Imfinzi + Lynparza as maintenance treatment vs CT alone to treat newly diagnosed advanced/recurrent endometrial cancer patients (n=699)
- The analysis demonstrated PFS of 43% (median: 15mos. vs 9.7mos.) in pMMR patients and 58% (median not attained vs 7mos.) in dMMR patients
Ref: AstraZeneca | Image: AstraZeneca
Related News:- Merck Discontinues the P-III (KEYLYNK-008) Study of Keytruda (pembrolizumab) + Lynparza (olaparib) for Metastatic Squamous NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
